Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.46 USD

28.46
102,150,788

-0.40 (-1.39%)

Updated Oct 29, 2024 04:00 PM ET

After-Market: $28.52 +0.06 (0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 16% (40 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer (PFE) Begins Dosing in Prostate Cancer Drugs Study

by Zacks Equity Research

Pfizer (PFE) is developing its oral PARP inhibitor, talazoparib (Talzenna), in combination with Xtandi as a potential treatment for castration-sensitive prostate cancer in a late-stage study.

J&J (JNJ)/Bayer Seek Nod for Xarelto for Blood Clots in Kids

by Zacks Equity Research

J&J (JNJ) and its partner Bayer seek approval of Xarelto as a treatment and prevention for venous thromboembolism in pediatric patients.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod to AZN, SNY, JNJ Drugs, Glaxo's New COVID-19 Drug Data

by Kinjel Shah

EU approves AstraZeneca's (AZN) rare disease drug, Koselugo and expanded use of J&J's (JNJ) Darzalex Faspro and Sanofi's (SNY) Aubagio.

Halozyme (HALO) Inks Collaboration Deal With Glaxo's HIV Unit

by Zacks Equity Research

Halozyme (HALO) and Glaxo's HIV company, ViiV Healthcare sign a collaboration agreement, which gives the latter exclusive right to Halozyme's ENHANZE technology to develop therapies targeting HIV

Glaxo (GSK)/Vir Affirm COVID-19 Drug Cuts Hospitalization/Death

by Zacks Equity Research

Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make better HIV medicines.

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $39.42, moving +1.57% from the previous trading session.

AstraZeneca (AZN) Gets Court Order to Supply COVID-19 Jabs in EU

by Zacks Equity Research

A court in Brussels orders AstraZeneca (AZN) to supply 80 million doses of its COVID-19 vaccine to Europe by Sep 27, 2021. The European Commission had requested for 300 million doses by end of September.

Will Emergence of COVID-19 Delta Variant Aid Vaccine Makers?

by Zacks Equity Research

The new variant of COVID-19 virus, delta, is increasing the risk of infections across the globe. This will likely lead to higher demand for COVID-19 vaccines and therapeutics.

Kinjel Shah headshot

Pharma Stock Roundup: AZN COVID-19 Antibody Cocktail Failure, GSK New Cancer Deal

by Kinjel Shah

AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.

CureVac (CVAC) Plummets on Disappointing COVID-19 Vaccine Data

by Zacks Equity Research

CureVac (CVAC) down as it announces that its first-generation COVID-19 vaccine candidate, CVnCoV, did not meet the prespecified statistical success criteria in a phase IIb/III study.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed at $39.63 in the latest trading session, marking a -1.3% move from the prior day.

Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension

by Zacks Equity Research

Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.

J&J (JNJ) Gets FDA Nod for 10M COVID Vaccines, Discards Many

by Zacks Equity Research

J&J (JNJ) gets authorization for two batches of COVID-19 vaccine doses manufactured at Baltimore facility but the FDA discards several others. Europe and Canada stop the rollout of some batches of the vaccine.

AstraZeneca (AZN) COVID-19 Jab's New Side Effect Stated by EMA

by Zacks Equity Research

The PRAC of the European Medicines Agency (EMA) has advised against giving AstraZeneca's (AZN) Vaxzevria COVID-19 vaccine to people with a history of capillary leak syndrome, a rare blood disorder.

Company News for Jun 11, 2021

by Zacks Equity Research

Companies in the news are: SIG, XIN, VRNA, PFE

Indrajit Bandyopadhyay headshot

COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart

by Indrajit Bandyopadhyay

The CDC reports cases of myocarditis and pericarditis following inoculation with mRNA vaccines of Moderna (MRNA) and Pfizer (PFE). The authority schedules meeting next week to investigate these reports.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approval for NVO, PFE Products & Other Updates

by Kinjel Shah

FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.

Merck (MRK) Signs $1.2B Deal With US for COVID-19 Therapeutic

by Zacks Equity Research

Merck (MRK) is set to supply 1.7 million courses of its oral COVID-19 therapy candidate, molnupiravir, worth $1.2 billion to the U.S. government, following a potential approval or authorization.

Pfizer (PFE) Gets FDA Nod for Pneumococcal Vaccine Prevnar 20

by Zacks Equity Research

Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $38.85, moving -0.36% from the previous trading session.

Moderna (MRNA) Seeks Approval for COVID-19 Vaccine in Teens

by Zacks Equity Research

Moderna (MRNA) is seeking authorization for conditional use of its COVID-19 vaccine, mRNA-1273, in adolescents in Europe and Canada.

Pfizer (PFE) Down 3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $38.79, marking a +0.75% move from the previous day.

Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More

by Zacks Equity Research

The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.

Moderna (MRNA) Files for Full Approval of COVID-19 Vaccine

by Zacks Equity Research

Moderna (MRNA) seeks full approval for its COVID-19 vaccine, mRNA-1273, in adults with initiation of rolling submission of a BLA. The company also boosts manufacturing capacity for the vaccine.